Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Omeros Corporation Stock Rose as Much as 16.7% Today

By Maxx Chatsko - Updated Jun 13, 2017 at 5:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biopharma received some great regulatory news from the FDA.

What happened

Shares of Omeros Corporation (OMER 12.40%) surged nearly 17% on Tuesday after the company announced that the U.S. Food and Drug Administration had granted its lead drug candidate breakthrough therapy designation. OMS721 is set to begin its second phase 3 trial later this year and is being evaluated as a potential treatment for Immunoglobulin A (IgA) nephropathy, a rare form of kidney disease. 

The classification was granted based on the drug candidate's phase 2 data, which included a 73% mean reduction in 24-hour urine protein levels after 12 weeks of treatment. The designation may allow OMS721 an easier path to marketing approval. As of 3:43 p.m. EDT, the stock had settled to a 15.8% gain.

A man on his laptop being showered in cash.

Image source: Getty Images.

So what

Omeros has one commercial product on the market today and a robust pipeline chock-full of potential. Omidria, which is approved for use during two different types of eye surgeries and procedures, has been steadily growing sales for the past several quarters. However, the company is heavily leveraged -- with a debt-to-assets ratio exceeding 100% -- and desperately needs to grow its way out from under its debt pile.

Omidria is slowly delivering, but investors are looking to the pipeline as well. OMS721 is the most advanced drug candidate, currently being evaluated in a phase 3 trial for atypical hemolytic uremic syndrome. In addition to awaiting the commencement of a phase 3 trial in IgA nephropathy, it recently concluded a phase 2 trial in hematopoietic stem cell transplant-associated TMA. 

Now what

The news today is being welcomed by investors for two simple reasons. First, breakthrough therapy designation is always a boon for drug development. Second, it offers the potential for Omeros to improve its financial position faster than what may be expected from "normal" regulatory pathways. The immediate impact is not significant, but it could end up lifting the company and its shareholders in the long term.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Omeros Corporation Stock Quote
Omeros Corporation
$2.72 (12.40%) $0.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.